1. Eplontersen: First Approval.
- Author
-
Nie, Tina
- Subjects
- *
LIGANDS (Chemistry) , *CARBOHYDRATES , *HEALTH status indicators , *CARDIAC amyloidosis , *AMYLOIDOSIS , *MEDICATION error prevention , *PATIENT care , *NUCLEOTIDES , *DRUG approval , *MESSENGER RNA , *POLYNEUROPATHIES , *AMYLOID plaque , *QUALITY of life , *DRUG development , *LIVER , *SERUM albumin , *SUBCUTANEOUS injections , *DISEASE progression - Abstract
Eplontersen (Wainua™) is a ligand-conjugated antisense oligonucleotide directed to TTR, which is being developed by Ionis Pharmaceuticals and AstraZeneca for the treatment of TTR-mediated amyloidosis (ATTR). Eplontersen, which is targeted to the liver by a ligand containing three N-acetyl galactosamine residues, binds to wild-type and variant TTR mRNA, thus reducing the levels of circulating TTR protein and amyloid deposition. Subcutaneous eplontersen reduced serum TTR levels, inhibited neuropathy progression and improved health-related quality of life in patients with polyneuropathy of hereditary ATTR (ATTRv-PN; v for variant) in a phase III trial. Based on these results, eplontersen was approved in the USA for the treatment of ATTRv-PN on 21 December 2023 and is currently undergoing regulatory review for a similar indication in the EU, the UK, Switzerland and Canada. Eplontersen is also undergoing phase III development for ATTR cardiomyopathy. This article summarizes the milestones in the development of eplontersen leading to this first approval for ATTRv-PN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF